UK Interleukin Inhibitors Market, Size, Share, Analysis Report & Forecast to 2026

The UK Interleukin Inhibitors market is projected to grow at a modest CAGR of 8.5% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the rise in the prevalence of various disorders such as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. As per the Institute for Health Metrics and Evaluation, the prevalence of asthma was 5.9 million in 2017 which increased up to 6.4 million. The prevalence of inflammatory bowel disease (IBD) was more than 187,000 in 2017 which increased to more than 195,000 in 2019. Whereas, the prevalence of psoriasis was approximately 1.4 million in 2019. Hence, for the treatment of such severe diseases, there is an increased demand for advanced treatment drugs.

Free Sample Copy @ https://www.omrglobal.com/request-sample/uk-interleukin-inhibitors-market

The UK Interleukin Inhibitors market is segmented on the basis of product type and applications. Based on the product type, the market is segmented as IL-1 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, and IL-23 inhibitors. The IL-17 inhibitors segment is likely to register a significant market value over the forecast period. Based on the applications, the market is segmented as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. The inflammatory bowel disease (IBD) segment is likely to register a significant market value over the forecast period.

A Full Report of UK Interleukin Inhibitors Market is Available at:
https://www.omrglobal.com/industry-reports/uk-interleukin-inhibitors-market

Furthermore, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KgaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. are some of the prominent players functioning in the UK Interleukin Inhibitors market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.

UK Interleukin Inhibitors Market – Segmentation
by Product Type
IL-1 Inhibitors
IL-5 Inhibitors
IL-6 Inhibitors
IL-17 Inhibitors
IL-23 Inhibitors
by Application
Arthritis
Asthma
Eczema
Inflammatory Bowel Disease (IBD)
Psoriasis
Others (Transplant Rejection)

Company Profiles
AbbVie, Inc.
AstraZeneca Plc
Bausch Health Co. Inc.
Bristol–Myers Squibb Co.
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson and Johnson Services Inc.
Merck KgaA
Novartis AG
Regeneron Pharmaceuticals, Inc.
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Industries, Ltd
Valeant Pharmaceuticals, Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-interleukin-inhibitors-market

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com 
Contact no: +91 780-304-0404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.